Denver, CONCT07102381Now EnrollingIRB Ready

Breast Cancer Clinical Trial in Denver, CO

Access cutting-edge breast cancer treatment through this phase 2 clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Jazz Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer treatment provided free

Apply for This Denver Location

Check if you qualify for this breast cancer clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Breast Cancer Study in Denver

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Sponsor: Jazz Pharmaceuticals

Who Can Participate

Inclusion Criteria

Has newly diagnosed Stage II or III histologically confirmed invasive breast carcinoma.
Has histologically confirmed HER2-positive breast cancer
Has a known hormone receptor (HR) status of the primary tumor
Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is HER2-positive, and the treating physician has determined the participant should be treated as HER2-positive.
Agrees to undergo a mastectomy or breast conserving surgery (BCS) after neoadjuvant therapy.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function
Has an LVEF ≥ 50% as determined by either ECHO or MUGA obtained within 6 weeks prior to randomization.
Adequate contraceptive precautions
Participants with known HIV are eligible unless:
CD4+ T Cell count is less than or equal to 350 microliters (uL)
Detectable viral load, or
Receiving protease inhibitors or cobicistat

Exclusion Criteria

Has Stage IV (metastatic) breast cancer.
Has bilateral breast cancer.
Has a history of any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator, could affect the participant's involvement in the study.
Has uncontrolled hypertension
Has significant symptoms from peripheral neuropathy
Has an active uncontrolled infection
Has a history of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in the drug formulation of zanidatamab or other study interventions.
Known active hepatitis B or C infection.
Has another malignancy diagnosed within the last 5 years. Exceptions include previously treated non melanomatous skin cancers, carcinoma in-situ, and melanoma in-situ. Participants with prior ipsilateral ductal carcinoma in situ (DCIS) or invasive breast cancer are not eligible.
Was treated with surgery, chemotherapy, anti-HER2 therapy, radiation therapy, endocrine therapy, or experimental therapy for invasive breast cancer
Is planning to receive concurrent therapy with any other investigational agent or anti-cancer therapy not specified in the protocol
Receipt of a live vaccine within 4 weeks prior to enrollment
Has a known hypersensitivity to any components of the study interventions, including chemotherapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT07102381) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in Denver, CO

If you're searching for breast cancer treatment options in Denver, CO, this clinical trial (NCT07102381) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Denver, CO

See all breast cancer clinical trials recruiting in Denver — not just this study.

Browse Breast Cancer Trials in Denver →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO